

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**LISTING OF CLAIMS:**

1. (Original) A pharmaceutical composition for the treatment of diseases related to gastric hyperacidity, wherein it contains a combination of one or more histamine H2-receptor antagonists and tenatoprazole.

2. (Original) The composition according to claim 1, wherein the histamine H2-receptor antagonist is selected from cimetidine, ranitidine, famotidine and nizatidine.

3. (Currently Amended) The composition according to ~~either claim 1 or claim 2~~ claim 1, wherein the weight ratio between tenatoprazole and the histamine H2-receptor antagonist is between 1:30 and 1:2.

4. (Currently Amended) The composition according to ~~any of the preceding claims~~ claim 1, wherein it contains between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H2-receptor antagonist.

5. (Original) The composition according to claim 1, wherein tenatoprazole is in the form of a potassium, magnesium, sodium or calcium salt.

6. (Currently Amended) The composition according to ~~any of the preceding claims~~ claim 1, wherein it is presented in a form for oral or parenteral administration.

Claim 7 (Cancelled)

Claim 8 (Cancelled)

9. (New) The composition according to claim 2, wherein the weight ratio between tenatoprazole and the histamine H<sub>2</sub>-receptor antagonist is between 2:30 and 1:2.

10. (New) The composition according to claim 2, wherein it contains between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine 1H<sub>3</sub>-receptor antagonist.

11. (New) The composition according to claim 3, wherein it contains between 10 and 60 mg of tenatoprazole and between 40 and 400 mg of a histamine H<sub>2</sub>-receptor antagonist.

12. (New) The composition according to claim 2, wherein it is presented in a form for oral or parenteral administration.

13. (New) The composition according to claim 3, wherein it is presented in a form for oral or parenteral administration.

14. (New) The composition according to claim 4, wherein it is presented in a form for oral or parenteral administration.

15. (New) The composition according to claim 5, wherein it is presented in a form for oral or parenteral administration.

16. (New) A medicinal product useful for the treatment of diseases related to gastric hyperacidity comprised of tenatoprazole and at least one histamine H2-receptor antagonist.

17. (New) A method of treating diseases relating to gastric hyperacidity which comprises administering a medical product composed of tenatoprazole and at least one histamine H2-receptor antagonist.

18. (New) The method of claim 17, wherein the treatment is for gastric and duodenal ulcers, and symptoms and lesions related to gastroesophageal reflux.